Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Abstract: The invention relates to a battery device (10) for a motor vehicle, having a plurality of battery cells (12) which are accommodated in a housing and rest at least against a heat-conducting potting compound (20) or a heat-conducting pad, which potting compound or pad rests against at least one structural component (22) of the battery device (10), as a result of which heat (14) can be dissipated from the battery cells (12) to the structural component (22) via the heat-conducting potting compound (20) or the heat-conducting pad.

Abstract: In one embodiment, a method for scheduling tasks comprises, at a task scheduler of a processing node of a plurality of processing nodes: retrieving a first task descriptor from a local memory of the task scheduler, the task descriptor corresponding to a task scheduled for execution at the current time and comprising at least a task execution time, a frequency for performing the task, and a task identifier; determining whether the task descriptor is assigned to the task scheduler for execution; if it is determined that the task descriptor is assigned to the task scheduler for execution: executing the task; updating the task execution time based on the current task execution time and the frequency for performing the task; and re-queuing the task descriptor in the local memory.

Abstract: Apparatuses (e.g., devices, systems, etc.) and methods that may provide access to one or more tools to a remote site in the body including expandable and external working channels that may be part of a tube that is coupled to an outer surface of an elongate medical device, such as an endoscope.

Abstract: A process to form a rheology modified composition, the process comprising applying radiation, and optionally heat, to a composition that comprises at least the following component: a) an olefin-based polymer comprising a total unsaturation ?0.20 /1000 C; and wherein the radiation is applied using an electron beam (e-beam) at a dosage selected from 0.1 MRad to 1.5 MRad; and wherein component a is selected from a telechelic polyolefin of the formula A1L1L2A2, an unsaturated polyolefin of the formula A1L1, or an ethylene/alpha-olefin interpolymer. A process to form a rheology modified composition, the process comprising applying heat, and optionally radiation, to a composition that comprises at least the following components: a) an olefin-based polymer, as described above, comprising a total unsaturation ?0.20/1000 C; b) from 1.0 to 100 ppm of a peroxide, based on the weight of the composition.

Abstract: An optical assembly (100) for use in a wearable device is provided, the assembly (100) comprising: a prism (104), a photonic integrated chip, PIC (108), a substrate layer (106), and a lid (102); wherein the PIC (108) is mounted onto the substrate layer (106); the prism (104) comprising: (i) a first input/output surface (112) optically coupled to the PIC (108), and (ii) a second input/output surface (114) optically coupled to the lid (102), the second input/output surface (114) orientated perpendicularly to the first input/output surface (112), and wherein the prism (104) provides an optical path and reflects a percentage of light from the first input/output surface (112) to the second input/output surface (114). Methods of manufacturing such an optical assembly are also provided.

Abstract: A lab system identifies a set of steps associated with a protocol for a lab meant to be performed by a robot within the lab using equipment and reagents. The lab system renders, within a user interface, a virtual representation of the lab, a virtual robot, and virtual equipment and reagents. Responsive to operating in a first mode, the lab system simulates the identified set of steps identify virtual positions of the virtual robot within the lab as the virtual robot performs the steps and modifies the virtual representation of the lab to mirror the identified positions of the virtual robot in real-time. Responsive to operating in a second mode, the lab system identifies positions of the robot within the lab as the robot performs the identified set of steps and modifies the virtual representation of the lab to mirror the identified positions of the robot in real-time.

Abstract: A lab system accesses a first protocol for performance by a first robot in a first lab. The first protocol includes a set of steps, each associated with an operation, reagent, and equipment. For each of one or more steps, the lab system modifies the step by: (1) identifying one or more replacement operations that achieve an equivalent or substantially similar result as a performance of the operation, (2) identifying replacement equipment that operates substantially similarly to the equipment, and/or (3) identifying one or more replacement reagents that, when substituted for the reagent, do not substantially affect the performance of the step. The lab system generates a modified protocol by replacing one or more of the set of steps with the modified steps. The lab system selects a second lab including a second and configures the second robot to perform the modified protocol in the second lab.

Abstract: Provided are compositions related to HSD17B13 variants, including nucleic acid molecules and polypeptides related to variants of HSD17B13, and cells comprising those nucleic acid molecules and polypeptides. Also provided are methods related to HSD17B3 variants. Such methods include methods for detecting the presence of the HSD17B13 rs72613567 variant in a biological sample comprising genomic DNA, for detecting the presence or levels of any one of variant HSD17B13 Transcripts C, D, E, F, G, and H, and particularly D, in a biological sample comprising mRNA or cDNA, or for detecting the presence or levels of any one of variant HSD17B13 protein Isoforms C, D, E, F, G, or H, and particularly D, in a biological sample comprising protein. Also provided are methods for determining a subject's susceptibility to developing a liver disease or of diagnosing a subject with liver disease.

Abstract: Provided are compositions related to HSD17B13 variants, including nucleic acid molecules and polypeptides related to variants of HSD17B13, and cells comprising those nucleic acid molecules and polypeptides. Also provided are methods related to HSD17B13 variants. Such methods include methods for detecting the presence of the HSD17B13 rs72613567 variant in a biological sample comprising genomic DNA, for detecting the presence or levels of any one of variant HSD17B13 Transcripts C, D, E, F, G, and H, and particularly D, in a biological sample comprising mRNA or cDNA, or for detecting the presence or levels of any one of variant HSD17B13 protein Isoforms C, D, E, F, G, or H, and particularly D, in a biological sample comprising protein. Also provided are methods for determining a subject's susceptibility to developing a liver disease or of diagnosing a subject with liver disease.

Abstract: The present disclosure provides methods of treating subjects having an inflammatory disease, and methods of identifying subjects having an increased risk of developing an inflammatory disease.

Abstract: The present disclosure provides methods of treating subjects having varicose veins or at risk of developing varicose veins, methods of identifying subjects having an increased risk of developing varicose veins, and methods of detecting Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) variant nucleic acid molecules and variant polypeptides.

Abstract: Provided are compositions related to HSD17B13 variants, including isolated nucleic acids and proteins related to variants of HSD17B13, and cells comprising those nucleic acids and proteins. Also provided are methods related to HSD17B13 variants. Such methods include methods for modifying a cell through use of any combination of nuclease agents, exogenous donor sequences, transcriptional activators, transcriptional repressors, and expression vectors for expressing a recombinant HSD17B13 gene or a nucleic acid encoding an HSD17B13 protein. Also provided are therapeutic and prophylactic methods for treating a subject having or at risk of developing chronic liver disease.

Abstract: The present disclosure provides methods of treating subjects having hypertension, coronary heart disease, and/or atrial fibrillation or at risk of developing hypertension, coronary heart disease, and/or atrial fibrillation, methods of identifying subjects having an increased risk of developing hypertension, coronary heart disease, and/or atrial fibrillation, and methods of detecting Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) variant nucleic acid molecules and variant polypeptides.

Abstract: The present disclosure provides methods of treating a subject having a metabolic disorder or is at risk of developing a metabolic disorder or preventing a subject from developing a metabolic disorder, and methods of identifying subjects having an increased risk of developing a metabolic disorder.

Abstract: The present disclosure provides methods of treating a subject having asthma or at risk of developing asthma, and methods of identifying subjects having an increased risk of developing asthma.

Abstract: The present disclosure provides methods of treating subjects having skin cancer or at risk of developing skin cancer, and methods of identifying subjects having an increased risk of developing skin cancer.

Abstract: Provided are compositions related to HSD17B13 variants, including isolated nucleic acids and proteins related to variants of HSD17B13, and cells comprising those nucleic acids and proteins. Also provided are methods related to HSD17B13 variants. Such methods include methods for modifying a cell through use of any combination of nuclease agents, exogenous donor sequences, transcriptional activators, transcriptional repressors, and expression vectors for expressing a recombinant HSD17B13 gene or a nucleic acid encoding an HSD17B13 protein. Also provided are therapeutic and prophylactic methods for treating a subject having or at risk of developing chronic liver disease.

Abstract: Provided are compositions related to HSD17B13 variants, including nucleic acid molecules and polypeptides related to variants of HSD17B13, and cells comprising those nucleic acid molecules and polypeptides. Also provided are methods related to HSD17B13 variants. Such methods include methods for detecting the presence of the HSD17B13 rs72613567 variant in a biological sample comprising genomic DNA, for detecting the presence or levels of any one of variant HSD17B13 Transcripts C, D, E, F, G, and H, and particularly D, in a biological sample comprising mRNA or cDNA, or for detecting the presence or levels of any one of variant HSD17B13 protein Isoforms C, D, E, F, G, or H, and particularly D, in a biological sample comprising protein. Also provided are methods for determining a subject's susceptibility to developing a liver disease or of diagnosing a subject with liver disease.

Abstract: A lab system configures robots to performs protocols in labs. The lab automation system receives, via a user interface, an instruction from a user to perform a protocol within a lab. The instruction may comprise text, and the lab may comprise a robot configured to perform the protocol. The lab system converts, using a machine learned model, the text into steps and, for each step, identifies one or more of an operation, lab equipment, and reagent associated with the step. In response to detecting an ambiguity/error associated with the step, the lab system notifies the user via the user interface of the ambiguity/error. The lab system may receive one or more indications from the user that resolve the ambiguity/error and update the associated steps. For each step, the lab system configures the robot to perform an identified operation, interact with identified lab equipment, and/or access/use an identified reagent.